APOL1 was observed to be a critical enzyme in lipid functioning and metabolic processes and was found to be aberrantly highly expressed in hepatocellular carcinoma, small-cell lung cancer, and bladder cancer (41–44). This evidence concerns the gene APOL1 and urinary bladder cancer.